Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.
Aidoc Raises $150 Million Series E Led by Goldman Sachs to Scale Clinical AI for Earlier, Safer Diagnoses
The Funding Accelerates Expansion of Aidoc’s Clinical Foundation Model and Enterprise AI Platform to Combat Diagnostic Harm and Improve Efficiency Across Health Systems
Aidoc, a global leader in clinical AI, has raised $150 million in Series E funding led by Growth Equity at Goldman Sachs Alternatives. The round had participation from General Catalyst, SoftBank Vision Fund 2, and NVentures (NVIDIA’s venture capital arm). The round brings total funding to over $500 million, less than a year after a growth round led by General Catalyst and Square Peg. This underscores the pace of Aidoc’s momentum and the accelerating demand for enterprise-scale clinical AI.
Diagnostic errors and delays contribute to at least 400,000 deaths each year in the United States, driven by rising imaging volumes, workforce shortages, and growing clinical complexity. While AI has long promised to reduce that burden, most tools have tackled one use case at a time, limiting their impact at scale.
As hospitals seek broader, system-wide solutions, the market is shifting toward clinical AI deployed across entire health systems. Foundation models have made that shift technically possible by enabling expanded coverage across conditions and imaging modalities from a single architecture. Translating that capability into regulated, real-world care, however, has proven far more complex. Aidoc developed its own clinical foundation model, CARE, and deployed it through its enterprise platform, aiOS. Earlier this year, CARE received a landmark first FDA clearance for a comprehensive double-digit foundation model-based triage system in clinical imaging. Today, the company analyzes more than 60 million patient cases annually and is deployed across nearly 2,000 hospitals, signaling a new phase in the adoption of clinical AI.
“By 2030, every complex diagnostic decision should be supported by AI that enables earlier detection and reduces preventable error,” said Elad Walach, Co-Founder and CEO at Aidoc. “We feel a deep responsibility to deploy CARE safely and at scale across health systems. This funding accelerates comprehensive disease coverage and advances end-to-end AI across CT and X-ray, spanning the full workflow, including pixel to draft report within two years.”
As clinical AI moves to enterprise deployment, a determining factor is governance and regulatory discipline. In large, complex health systems, scale requires not only advanced technology but the oversight and accountability needed to operate safely in real-world care.
“Aidoc pairs advanced technology with regulatory rigor in a way that few companies have achieved,” said Christian Resch, Partner at Growth Equity at Goldman Sachs Alternatives…
Full release here, originally announced April 29th, 2026.
Iterative Health Closes $77 Million Series C to Accelerate the Future of Clinical Research
Led by Intrepid Growth Partners and GV (Google Ventures), Funding Advances Iterative Health’s Position as the Leading Multispecialty Clinical Research Network
Iterative Health, a healthcare technology and services company powering the acceleration of clinical research, today announced the close of a $77 million Series C financing round. The round was led by Intrepid Growth Partners and GV (Google Ventures), joined by new investors EDBI (arm of SG Growth Capital, the investment platform of EDB and Enterprise Singapore) and a prominent family office, and participation from existing investors such as Insight Partners and Obvious Ventures.
Clinical trials are critical in bridging scientific discovery and patient care; however, systematic challenges delay the delivery of new therapies to patients who need them most. More than half of research sites enroll one or fewer patients per study, and nearly 90% of US-based trials fail to meet enrollment targets on time, underscoring the constraints on sites operating in an increasingly complex research environment.
Iterative Health is addressing these challenges by building a high-performing, multispecialty clinical research network that embeds research directly into clinical care. Unique from traditional research networks, the company places site success at the center of trial execution. By combining centralized operations, expert staffing, proprietary AI technology, and deep clinical trial expertise, Iterative Health developed a proven site-serving model for sustained site success and reliable trial execution. Sponsors and CROs gain centralized access to industry-leading sites and diverse patient populations, accelerating trials to advance the future of care.
Today, Iterative Health’s global network includes more than 100 research sites across North America, Europe, India, and Australia, as well as partnerships with over 40 pharmaceutical, biotech, medical device, and contract research organizations. Compared to industry benchmarks for IBD trials, the network delivers 2x faster site activation, reducing startup timelines by up to 3 months, and 3x higher patient enrollment rates, with an average of more than two IBD patients randomized every business day across the global site network.
“Every delay in a clinical trial is a delay for patients whose outcomes depend on faster access to innovation. By keeping our physician partners and their patients at the center of our model, we’ve built a system that delivers high-performance site execution at scale,” said Jonathan Ng, MBBS, Founder and CEO at Iterative Health…
Full release here, originally announced April 30th, 2026.
No comments:
Post a Comment